A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed ...

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

Neuroblastoma is the most common extracranial solid tumor in children and accounts for up to 15% of childhood cancer-related deaths worldwide. Neuroblastoma tumors are characterized by hypoxia, which ...

In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters.

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...